Medical Innovation Xchange Welcomes LND Therapeutics as Our Newest Affiliate Company
Medical Innovation Xchange Welcomes LND Therapeutics as our Newest Affiliate Company
Kitchener, Ontario – November 16, 2026 Medical Innovation Xchange (MIX) is thrilled to welcome LND Therapeutics as the newest Affiliate member. At LND Therapeutics, they are harnessing the power of the microbiome to help more cancer patients benefit from immunotherapy through LND101, an oral microbiome therapeutic designed to modify the gut microbiome and enhance immunotherapy.
LND Therapeutics chose to join MIX because of its unique combination of mentorship, financial support, strategic partnerships, investor visibility, and regulatory expertise that can help accelerate their path to commercialization.
The company is particularly excited about collaborating with the MIX community to advance microbiome innovation, build strategic partnerships, and prepare LND101 for larger-scale clinical and commercial success.
MIX is excited to welcome LND Therapeutics in our ecosystem and support their journey bringing their solution to clinics and patients. Their mission aligns deeply with our vision for advancing Canadian medical and health innovation and working together with healthcare, technology, and innovation ecosystem.
Learn more about MIX or explore how to join our community by visiting MIX Programs.
